A star drug in Mallinck­rodt’s $1.2B Su­cam­po buy­out flops in piv­otal tri­al

Some of the in­sid­ers at Mallinck­rodt $MNK may be won­der­ing to­day why they paid $1.2 bil­lion for Su­cam­po just 10 months ago. One of the two late-stage drugs they bagged in the deal has failed the reg­is­tra­tion study for of­ten fa­tal cas­es of Nie­mann-Pick type C.

Billed as a rel­a­tive­ly eco­nom­i­cal ap­proach to build­ing their late-stage pipeline, Mallinck­rodt — which was drummed out of PhRMA af­ter be­com­ing a punch­ing bag for crit­ics due to its pric­ing strat­e­gy — told in­vestors Tues­day that VTS-270 flopped in the reg­is­tra­tion study.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.